Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note published on Saturday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Stock Down 23.7 %

CHEK stock opened at $1.35 on Friday. Check-Cap has a twelve month low of $0.56 and a twelve month high of $3.45. The company has a market cap of $7.90 million, a price-to-earnings ratio of -0.45 and a beta of 0.17. The business has a 50 day moving average price of $0.96 and a two-hundred day moving average price of $1.49.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.